Association of symptomatic benign prostatic hyperplasia and prostate cancer: Results from the prostate cancer prevention trial

American Journal of Epidemiology

Volumn 173, Issue 12, 2011, Pages 1419-1428

  Schenk, Jeannette M ^a,b   Kristal, Alan R ^a,b   Arnold, Kathryn B ^a   Tangen, Catherine M ^a   Neuhouser, Marian L ^a,b   Lin, Daniel W ^a,c   White, Emily ^a,b   Thompson, Ian M ^d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

bias (epidemiology); prostatic hyperplasia; prostatic neoplasms

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

ANTIGEN; BODY MASS; CANCER; DISEASE PREVALENCE; EPIDEMIOLOGY; HEALTH RISK; REPRODUCTIVE BIOLOGY; REPRODUCTIVE DISORDER; SYMPTOM; TEMPORAL ANALYSIS;

ADULT; AGE; AGED; ARTICLE; BIOPSY; BODY MASS; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; DISEASE ASSOCIATION; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; RACE;

5-ALPHA REDUCTASE INHIBITORS; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 79958849395     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwq493     Document Type: Article

References (36)

1. Turner RD, Belt E. The results of 1,694 consecutive simple perineal prostatectomies. J Urol. 1957;77(6):853-863.
2. Sommers SC. Endocrine changes with prostatic carcinoma. Cancer. 1957;10(2):345-358.
3. Labess M. Occult carcinoma in clinically benign hypertrophy of the prostate; a pathological and clinical study. J Urol. 1952;68(6):893-896.
4. Bostwick DG, Cooner WH, Denis L, et al. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer. 1992;70(suppl 1):291-301.
5. Ornstein DK, Rao GS, Smith DS, et al. The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate. J Urol. 1997;157(3):880-883; discussion 883-884.
6. Sheldon CA,Williams RD, Fraley EE. Incidental carcinoma of the prostate: a review of the literature and critical reappraisal of classification. J Urol. 1980;124(5):626-631. (Pubitemid 11195763)
7. Hølund B. Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol. 1980;14(1):29-35. (Pubitemid 10107953)
8. Armenian HK, Lilienfeld AM, Diamond EL, et al. Relation between benign prostatic hyperplasia and cancer of the prostate. A prospective and retrospective study. Lancet. 1974;2(7873):115-117.
9. Chokkalingam AP, Nyrén O, Johansson JE, et al. Prostate carcinoma risk subsequent to diagnosis of benign prostatic hyperplasia: a population-based cohort study in Sweden. Cancer. 2003;98(8):1727-1734. (Pubitemid 37238630)
10. Lee C. Role of androgen in prostate growth and regression: stromal-epithelial interaction. Prostate Suppl. 1996;6:52-56. (Pubitemid 26112289)
11. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338(9):557-563. (Pubitemid 28114643)
12. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224. (Pubitemid 36859473)
13. Shah US, Getzenberg RH. Fingerprinting the diseased prostate: associations between BPH and prostate cancer. J Cell Biochem. 2004;91(1):161-169.
14. Schenk JM, Kristal AR, Neuhouser ML, et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Am J Epidemiol. 2010;171(5):571-582.
15. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7(4):256-269. (Pubitemid 46486616)
16. De Marzo AM, Coffey DS, NelsonWG. New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology. 1999;53(3 suppl. 3a):29-39; discussion 39-42.
17. Foster CS. Pathology of benign prostatic hyperplasia. Prostate Suppl. 2000;9:4-14.
18. Schröder FH, Blom JH. Natural history of benign prostatic hyperplasia (BPH). Prostate Suppl. 1989;2:17-22. (Pubitemid 20075617)
19. McNeal JE, Redwine EA, Freiha FS, et al. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol. 1988; 12(12):897-906. (Pubitemid 19011040)
20. Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer. Int J Cancer. 1977;20(5):680-688. (Pubitemid 8218533)
21. Jacobsen SJ, Girman CJ, Guess HA, et al. Do prostate size and urinary flow rates predict health care-seeking behavior for urinary symptoms in men? Urology. 1995;45(1):64-69.
22. Meigs JB, Barry MJ, Giovannucci E, et al. High rates of prostate-specific antigen testing in men with evidence of benign prostatic hyperplasia. Am J Med. 1998;104(6): 517-525. (Pubitemid 28328763)
23. Meigs JB, Barry MJ, Oesterling JE, et al. Interpreting results of prostate-specific antigen testing for early detection of prostate cancer. J Gen Intern Med. 1996;11(9):505-512. (Pubitemid 26353207)
24. Carroll P, Coley C, McLeod D, et al. Prostate-specific antigen best practice policy-part I: early detection and diagnosis of prostate cancer. Urology. 2001;57(2):217-224. (Pubitemid 32140792)
25. Uzzo RG, Wei JT, Waldbaum RS, et al. The influence of prostate size on cancer detection. Urology. 1995;46(6): 831-836.
26. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association Symptom Index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549-1557; discussion 1564.
27. McNutt LA,Wu C, Xue X, et al. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003;157(10):940-943. (Pubitemid 36555054)
28. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol. 2005;162(3):199-200. (Pubitemid 41373523)
29. Gong Z, Kristal AR, Schenk JM, et al. Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer. 2009;115(16):3661-3669.
30. Kristal AR, Arnold KB, Schenk JM, et al. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Am J Epidemiol. 2008;167(8):925-934. (Pubitemid 351521732)
31. Gong Z, Agalliu I, Lin DW, et al. Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men. Cancer Causes Control. 2008;19(1):25-31.
32. Hiatt RA, Armstrong MA, Klatsky AL, et al. Alcohol consumption, smoking, and other risk factors and prostate cancer in a large health plan cohort in California (United States). Cancer Causes Control. 1994;5(1):66-72. (Pubitemid 24066595)
33. Simons BD, Morrison AS, Young RH, et al. The relation of surgery for prostatic hypertrophy to carcinoma of the prostate. Am J Epidemiol. 1993;138(5):294-300. (Pubitemid 23263600)
34. Greenwald P, Kirmss V, Polan AK, et al. Cancer of the prostate among men with benign prostatic hyperplasia. J Natl Cancer Inst. 1974;53(2):335-340.
35. Jacobsen SJ, Guess HA, Panser L, et al. A population-based study of health care-seeking behavior for treatment of urinary symptoms. The Olmsted County Study of Urinary Symptoms and Health Status among men. Arch Fam Med. 1993;2(7):729-735.
36. Marks LS, Dorey FJ, Rhodes T, et al. Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia. J Urol. 1996;156(3):1035-1039. (Pubitemid 26269825)